Another target trial emulation evaluated stopping versus continuing treatment with mineralocorticoid receptor antagonists (a drug treatment that increases levels of potassium as a side effect) in people with chronic kidney disease and raised levels of blood potassium (ie, hyperkalaemia).12 Here, NR3C2 is linked to Hyperkalemia.